60% Type 2 Diabetes Patients Reach Glucose Targets with Avandia Plus Metformin
New data being presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that the combination of AVANDIA (rosiglitazone maleate) and metformin enabled over 60 percent of patients to achieve the glucose target of ≤ 7 percent HbA1c and nearly 40 percent of patients to reach the more stringent goal of ≤ 6.5 percent HbA1c.* In addition, the results of this six-month, real-life study involving 11,014 patients demonstrate that AVANDIA and metformin in combination reduced patients' blood pressure.1
"These new data are exciting as they demonstrate that by using the combination of AVANDIA plus metformin physicians in daily practice can now effectively control their type 2 diabetes patients' blood sugar levels to international treatment goals," said lead investigator, Dr Christoph Rosak from the Department of Metabolic Disease, Krankenhaus Sachsenhausen, Frankfurt, Germany. "Controlling glucose levels to targets of less than 6.5 to 7 percent HbA1c has previously been challenging, particularly as conventional monotherapy fails to control blood glucose over the long-term. Our new data also show that in the population studied AVANDIA plus metformin had the extra benefit of lowering patients' blood pressure."
Currently, only about 30 percent of people with type 2 diabetes have glucose levels below recommended targets of 6.5 to 7 percent HbA1c.2 In uncontrolled patients, chronic levels of high blood sugar can cause tissue and organ damage and can lead to serious complications such as cardiovascular disease, amputation and blindness.3 As type 2 diabetes is a progressive disease, the longer patients remain uncontrolled, the more extensive the damage and the harder it is to get the disease under control. Effective treatment of hypertension is also critically important in the management of patients with type 2 diabetes to reduce the risk of the devastating complications of the disease.4,5
AVANDIA helps to control blood sugar because it directly targets insulin resistance, an underlying cause of type 2 diabetes.6 Research has demonstrated that insulin resistance is also an independent risk factor for cardiovascular disease7 and that AVANDIA may have a positive effect on certain cardiovascular risk markers associated with type 2 diabetes such as blood pressure8 and HDL cholesterol.9 When combined with metformin, which works primarily by reducing the amount of sugar produced by the liver,10 these two drugs with complementary modes of action can help patients achieve enhanced glucose control, which in turn may slow disease progression and reduce the risk of long-term complications.11 The combination of AVANDIA plus metformin has also been shown to have a low risk of hypoglycaemia (low blood sugar), a side effect commonly associated with other conventional therapies.12
The new study presented at EASD was a pooled analysis of two large observational studies of reallife daily practice in Germany. A total of 11,014 patients received AVANDIA and metformin combination therapy for six months and achieved:1
-- an improvement in the percentage of patients reaching HbA1c levels of ≤ 7 from 13.5% at baseline to 63.7% at 6 months
-- an improvement in the percentage of patients reaching HbA1c levels of ≤ 6.5 from 5.3% at baseline to 38.8% at 6 months
-- a significant reduction of 1.3 percent in median HbA1c levels from baseline (p
60% Diabetul zaharat de tip 2 de Acoperire a glucozei Þinte Pacienþii cu Avandia ? Plus Metformina - 60% Type 2 Diabetes Patients Reach Glucose Targets with Avandia Plus Metformin - articole medicale engleza - startsanatate